Inhibikase Therapeutics, Inc. Financing Cash Flow
Inhibikase Therapeutics, Inc. (IKT) reported Financing Cash Flow of $2.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$14.49K, a 145.60% decline year-over-year.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $2.90M.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $108.57M, a 8.91% increase year-over-year.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$134.13K, a 173.72% decline year-over-year.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $108.46M, a 4.82% increase from fiscal 2024.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $103.48M, a 1131.14% increase from fiscal 2023.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $8.41M.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$204.77K, a 100.50% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $2.88M 10-Q · filed 2026-08-11 | $111.45M derived: sum of 3 quarters · filed 2026-08-11 | $111.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.90M 10-Q · filed 2026-05-12 | $111.46M derived: sum of 2 quarters · filed 2026-05-12 | $111.33M derived: sum of 3 quarters · filed 2026-05-12 | $111.36M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $108.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $108.43M derived: sum of 2 quarters · filed 2026-03-26 | $108.46M derived: sum of 3 quarters · filed 2026-08-11 | $108.46M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$134.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$102.36K derived: sum of 2 quarters · filed 2026-08-11 | -$102.36K 10-Q · filed 2025-11-14 | $99.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $31.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $31.77K 10-Q · filed 2026-08-11 | $99.72M derived: sum of 3 quarters · filed 2026-08-11 | $99.90M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $99.68M derived: sum of 2 quarters · filed 2026-05-12 | $99.87M derived: sum of 3 quarters · filed 2026-05-12 | $103.11M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $99.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $99.87M derived: sum of 2 quarters · filed 2026-03-26 | $103.11M derived: sum of 3 quarters · filed 2026-03-26 | $103.48M 10-K · filed 2026-03-26 |
| 2024-09-30 | $181.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.43M derived: sum of 2 quarters · filed 2025-11-14 | $3.79M 10-Q · filed 2025-11-14 | $3.66M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $3.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $3.61M 10-Q · filed 2025-08-14 | $3.47M derived: sum of 3 quarters · filed 2025-08-14 | $3.47M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $367.00K 10-Q · filed 2025-05-14 | $228.90K derived: sum of 2 quarters · filed 2025-05-14 | $228.97K derived: sum of 3 quarters · filed 2025-05-14 | $192.98K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$138.10K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$138.03K derived: sum of 2 quarters · filed 2025-03-27 | -$174.02K derived: sum of 3 quarters · filed 2025-03-27 | $8.41M 10-K · filed 2025-03-27 |
| 2023-09-30 | $70.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$35.92K derived: sum of 2 quarters · filed 2024-11-14 | $8.54M 10-Q · filed 2024-11-14 | $8.54M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$35.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $8.54M 10-Q · filed 2024-08-14 | $8.54M derived: sum of 3 quarters · filed 2024-08-14 | $8.54M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $8.58M 10-Q · filed 2024-05-15 | $8.58M derived: sum of 2 quarters · filed 2024-05-15 | $8.58M derived: sum of 3 quarters · filed 2024-05-15 | $8.58M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $0.00 derived: sum of 2 quarters · filed 2024-03-27 | $0.00 derived: sum of 3 quarters · filed 2024-03-27 | -$204.77K 10-K · filed 2024-03-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | -$204.77K 10-Q · filed 2023-11-14 | -$204.77K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$204.77K 10-Q · filed 2023-08-14 | -$204.77K derived: sum of 3 quarters · filed 2023-08-14 | -$174.88K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$204.77K 10-Q · filed 2023-05-15 | -$204.77K derived: sum of 2 quarters · filed 2023-05-15 | -$174.88K derived: sum of 3 quarters · filed 2023-05-15 | $41.30M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $29.89K derived: sum of 2 quarters · filed 2023-03-31 | $41.50M derived: sum of 3 quarters · filed 2023-03-31 | $41.09M 10-K · filed 2023-03-31 |
| 2021-09-30 | $29.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $41.50M derived: sum of 2 quarters · filed 2022-11-14 | $41.09M 10-Q · filed 2022-11-14 | $55.98M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $41.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $41.06M 10-Q · filed 2022-08-12 | $55.95M derived: sum of 3 quarters · filed 2022-08-12 | $55.88M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$409.66K 10-Q · filed 2022-05-16 | $14.47M derived: sum of 2 quarters · filed 2022-05-16 | $14.41M derived: sum of 3 quarters · filed 2022-05-16 | $14.40M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $14.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $14.82M derived: sum of 2 quarters · filed 2022-03-31 | $14.81M derived: sum of 3 quarters · filed 2022-03-31 | $15.06M 10-K · filed 2022-03-31 |
| 2020-09-30 | -$67.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$69.58K derived: sum of 2 quarters · filed 2021-11-15 | $180.54K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$2.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $247.67K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $250.12K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |